Zivo Bioscience, Inc.
ZIVO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001101026
No open-market purchases or sales by Zivo Bioscience, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17.6K in total; no superinvestor holds it.
Key figures
- Market capNo recent closing price
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 1
- 13F valueReported value at the end of Q2 2026
- $17.6K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- $157.2K
- +468.6% year over year
- Net income, FY2024
- -$13.4M
- No comparable prior period
- Free cash flow, FY2024
- –
- No comparable prior period
- Revenue, Q3 FY2025
- $65.6K
- +108.3% year over year
Revenue flow, FY2024
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2024: $13.4M (8513.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.73K
- Shares sold short
- Change
- −127
- −1.6% vs. previous
- Days to cover
- 8.49
- At average daily volume
Superinvestors holding ZIVO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ZIVO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Zivo Bioscience, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 24, 2026 (view filing)6:16 PM ET | Apr 17 | 7 daysLate | Strome Mark E and 2 others10% Owner | PPurchase | +100.0K | $2.00 | +$200.0K | +21.1%572.9K after | |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Yaldoo Laith LDirector, 10% Owner | PPurchase | +1.54K | $9.72 | +$15.0K | +0.3%583.6K after | |
| Feb 17, 2026 (view filing)6:22 AM ET | Feb 12 | 5 days | Strome Mark E and 2 others10% Owner | PPurchase | +20.0K | $9.77 | +$195.4K | +4.4%472.9K after | |
| Feb 17, 2026 (view filing)6:22 AM ET | Feb 12 | 5 days | Strome Mark E and 2 others10% Owner | PPurchase | +2.00K | $0.00 | $0 | –45.1K after | Derivative |
| Feb 12, 2026 (view filing) | Feb 10 | 2 days | Yaldoo Laith LDirector, 10% Owner | PPurchase | +2.43K | $10.27 | +$25.0K | +0.4%582.1K after | |
| Jan 28, 2026 (view filing) | Jan 26 | 2 days | Cornell Alison ADirector | PPurchase | +11.7K | $8.54 | +$100.0K | +4.4%279.5K after | |
| Jan 28, 2026 (view filing) | Jan 26 | 2 days | Payne John BernardPresident and CEO | PPurchase | +11.7K | $8.54 | +$100.0K | +148.0%19.6K after | |
| Jan 27, 2026 (view filing) | Jan 14 | 13 daysLate | Maggiore Christopher D.Director, 10% Owner | PPurchase | +1.77K | $8.49 | +$15.0K | +0.3%519.3K after | |
| Jan 27, 2026 (view filing) | Jan 14 | 13 daysLate | Yaldoo Laith LDirector, 10% Owner | PPurchase | +1.77K | $8.49 | +$15.0K | +0.3%579.6K after | |
| Dec 2, 2025 (view filing) | Nov 28 | 4 days | Yaldoo Laith LDirector, 10% Owner | PPurchase | +2.78K | $9.00 | +$25.0K | +0.5%577.9K after |
Top 10 13F holders, Q2 2026
See all 1 holdersThe largest institutional positions in Zivo Bioscience, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CoreCap Advisors, LLC | 4,360 | $17.6K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of ZIVO
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Zivo Bioscience, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Strome Mezzanine Fund, LP | 13D/A | 12.20%442.9K shares | – | Oct 30, 20233 filings | Jan 7, 2025 | SEC |
| Strome Mark E | 13D/A | 12.10%472.9K shares | – | Feb 27, 20261 filing | Feb 27, 2026 | SEC |